Abstract:Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II-IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data suggest patients with EGFR-mutant stage IB-IIIA resected NSCLC could benefit from adjuvant EGFR tyrosine kinase inhibitor treatment. We aimed to compare the efficacy of adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected EGFR-mutant stage II-IIIA (N1-N2) NSCLC. Methods We did a randomised, open-label, phase 3 trial at 27 centres in China. We enrolled patients aged 18-75 years with completely resected (R0), stage II-IIIA (N1-N2), EGFR-mutant (exon 19 deletion or exon 21 Leu858Arg) NSCLC. Patients were stratified by N stage and EGFR mutation status and randomised (1: 1) by Pocock and Simon minimisation with a random element to either gefitinib (250 mg once daily) for 24 months or intravenous vinorelbine (25 mg/m(2) on days 1 and 8) plus intravenous cisplatin (75 mg/m(2) on day 1) every 3 weeks for four cycles. The primary endpoint was disease-free survival in the intention-to-treat population, which comprised all randomised patients; the safety population included all randomised patients who received at least one dose of study medication. Enrolment to the study is closed but survival follow-up is ongoing. The study is registered with ClinicalTrials.gov, number NCT01405079. Findings Between Sept 19, 2011, and April 24, 2014, 483 patients were screened and 222 patients were randomised, 111 to gefitinib and 111 to vinorelbine plus cisplatin. Median follow-up was 36 . 5 months (IQR 23 . 8-44 . 8). Median disease-free survival was significantly longer with gefitinib (28 . 7 months [95% CI 24 . 9-32 . 5]) than with vinorelbine plus cisplatin (18 . 0 months [13 . 6-22 . 3]; hazard ratio [HR] 0 . 60, 95% CI 0 . 42-0 . 87; p=0 . 0054). In the safety population, the most commonly reported grade 3 or worse adverse events in the gefitinib group (n=106) were raised alanine aminotransferase and asparate aminotransferase (two [2%] patients with each event vs none with vinorelbine plus cisplatin). In the vinorelbine plus cisplatin group (n=87), the most frequently reported grade 3 or worse adverse events were neutropenia (30 [34%] patients vs none with gefitinib), leucopenia (14 [16%] vs none), and vomiting (eight [9%] vs none). Serious adverse events were reported for seven (7%) patients who received gefitinib and 20 (23%) patients who received vinorelbine plus cisplatin. No interstitial lung disease was noted with gefitinib. No deaths were treatment related. Interpretation Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC. Based on the superior disease-free survival, reduced toxicity, and improved quality of life, adjuvant gefitinib could be a potential treatment option compared with adjuvant chemotherapy in these patients. However, the duration of benefit with gefitinib after 24 months might be limited and overall survival data are not yet mature.

A Comparison of Efficacy and Toxicity Between Never-Smokers and Smokers with Lung Adenocarcinoma after Concurrent Gefitinib and Thoracic Radiotherapy

Epidermal Growth Factor Receptor Mutations Detected in Tumors from Chinese “never Smokers”with Lung Adenocarcinoma

Impact of Smoking on the Clinical Efficacy of Gefitinib Combined with Radiotherapy after Chemotherapy Failure in the Patients with Stages III and IV Non-Small-cell Lung Cancer

Efficacy and Safety Results from CurrentS, a Double-Blind, Randomized, Phase III Study of Second-Line Erlotinib (150 Mg Versus 300 Mg) in Current Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC).

Comparison of gefitinib and platinum-based chemotherapy and only platinum-based chemotherapy to treat lung adenocarcinoma

Characterization of Never-Smoking and Its Association with Clinical Outcomes in Chinese Patients with Small-Cell Lung Cancer

A Randomized, Double-Blind, Phase III Study Comparing Two Doses of Erlotinib for Second-Line Treatment of Current Smokers with Advanced Non-Small-cell Lung Cancer (Currents)

Gefitinib Versus Platinum Contained Doublet Chemotherapy in Chemotherapy-Naive Patients with Stage IIIb or IV Non-Small Cell Lung Cancer of Adenocarcinoma Histology: A Retrospective Case Control Study

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

Final Overall Survival and Updated Biomarker Analysis Results from the Randomized Phase Iii Icogen Trial

Influence of Smoking on the Efficency of Gefitinib in the Treatment of Advanced Non Small Cell Lung Cancer

Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer

[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].

Short-Term Effects of Gefitinib Combined with Three-Dimensional Conformal Radiotherapy on Advanced Non-Small-Cell Lung Cancer

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma.

[Evaluation of Efficacy and Safety of ZD1839 As Monotherapy in Chinese Patients with Advanced Non-Small Cell Lung Cancer].

Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC.

Gefitinib Versus Vinorelbine Plus Cisplatin As Adjuvant Treatment for Stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a Randomised, Open-Label, Phase 3 Study

Clinical Observation of Gefitinib for the Treatment of 125 Cases with Advanced Non-Small Cell Lung Cancer

Comparison of Survival in Patients with Advanced Lung Adenocarcinoma Treated Before and after Gefitinib Approval in China

Intercalating and Maintenance Use of Gefitinib Plus Chemotherapy Versus Chemotherapy Alone in Selected Advanced Nsclc(Iscan,Ctong-1102): A Multicentre, Open-Label, Randomised, Phase 3 Study.